GO
Loading...

AstraZeneca PLC

More

  • LONDON, April 20- U.S. pharmaceutical giant Pfizer has approached British rival AstraZeneca to propose a 60 billion pound takeover, Britain's Sunday Times reported.

  • New kind of trial aims to speed cancer drug development Wednesday, 16 Apr 2014 | 7:01 PM ET

    *AstraZeneca, Pfizer, UK charity link in multi-drug trial. Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.

  • April 15- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.

  • FDA approves GSK's Tanzeum to treat type 2 diabetes Tuesday, 15 Apr 2014 | 10:35 AM ET

    April 15- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • *Investors to get 0.8 Sun Pharma share per Ranbaxy share.

  • *AstraZeneca moving global HQ and R&D to Cambridge by 2016. CAMBRIDGE, England, March 31- AstraZeneca, which will complete its move to Cambridge by 2016, is already putting down roots in the ecosystem of the university city as it seeks to revitalise its drug research.

  • LONDON, March 27- Britain's healthcare agency NICE, which determines the use of treatments in the state-run health service, may be more likely to say' yes' to new drugs under proposals that enable it to take a broader view of the value they offer.

  • AstraZeneca raises bet on Japan by buying out Sumitomo Wednesday, 26 Mar 2014 | 3:21 AM ET

    LONDON, March 26- AstraZeneca has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical in its Japanese unit AstraZeneca K.K. The British group said on Wednesday the purchase of the shares cost approximately 10 billion yen and reinforced its focus on Japan as a key growth platform.

  • PARIS/ MOSCOW, March 21- U.S. and European sanctions against Russia are already having a ripple effect beyond their immediate targets, with Visa and MasterCard halting payment transaction services for clients of a bank not even on the blacklist. The lender described the move by Visa and MasterCard as unlawful.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • MUMBAI/ LONDON, March 11- Indian drugmaker Ranbaxy Laboratories Ltd is in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc's heartburn drug Nexium, a source said, to ensure the pills can be sold in the United States.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • Midday movers: Apple, FedEx, General Motors & More Monday, 3 Mar 2014 | 12:58 PM ET

    Some of Monday's midday movers:

  • Feb 25- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. Bristol-Myers said the FDA had asked it to conduct seven post-marketing studies on Myalept. The drugmaker had co-developed the drug with AstraZeneca.

  • *FDA chief says important for India to work with foreign regulators. MUMBAI, Feb 18- The head of the U.S. Food and Drug Administration called for more collaboration among regulators to improve drug quality and safety as she wrapped up a visit to India after recent import bans on drugs from a handful of plants in the country.

  • *More drugmakers could opt not to launch drugs in Germany. FRANKFURT/ BERLIN, Feb 18- Germany's plan to publish price discounts agreed with drugmakers poses a risk to profits in the industry, which fears the information could be used to drive down prices elsewhere.

Most Popular Video

Sunday, 20 Apr 2014 | 7:04 PM ET

While U.S. earnings remain an important market mover, Richard Jerram, Chief Economist at the Bank of Singapore, says attention will be on the China's HSBC flash purchasing managers' index.

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.